Eintrag weiter verarbeiten
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Blood, 120, 2012, 2, S. 291-294 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Marin, David Hedgley, Corinne Clark, Richard E. Apperley, Jane Foroni, Letizia Milojkovic, Dragana Pocock, Christopher Goldman, John M. O'Brien, Stephen Marin, David Hedgley, Corinne Clark, Richard E. Apperley, Jane Foroni, Letizia Milojkovic, Dragana Pocock, Christopher Goldman, John M. O'Brien, Stephen |
|---|---|
| author |
Marin, David Hedgley, Corinne Clark, Richard E. Apperley, Jane Foroni, Letizia Milojkovic, Dragana Pocock, Christopher Goldman, John M. O'Brien, Stephen |
| spellingShingle |
Marin, David Hedgley, Corinne Clark, Richard E. Apperley, Jane Foroni, Letizia Milojkovic, Dragana Pocock, Christopher Goldman, John M. O'Brien, Stephen Blood Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib Cell Biology Hematology Immunology Biochemistry |
| author_sort |
marin, david |
| spelling |
Marin, David Hedgley, Corinne Clark, Richard E. Apperley, Jane Foroni, Letizia Milojkovic, Dragana Pocock, Christopher Goldman, John M. O'Brien, Stephen 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2012-01-407486 <jats:title>Abstract</jats:title> <jats:p>Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693.</jats:p> Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib Blood |
| doi_str_mv |
10.1182/blood-2012-01-407486 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDEyLTAxLTQwNzQ4Ng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDEyLTAxLTQwNzQ4Ng |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Hematology, 2012 |
| imprint_str_mv |
American Society of Hematology, 2012 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
marin2012predictivevalueofearlymolecularresponseinpatientswithchronicmyeloidleukemiatreatedwithfirstlinedasatinib |
| publishDateSort |
2012 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_unstemmed |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_full |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_fullStr |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_full_unstemmed |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_short |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_sort |
predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2012-01-407486 |
| publishDate |
2012 |
| physical |
291-294 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693.</jats:p> |
| container_issue |
2 |
| container_start_page |
291 |
| container_title |
Blood |
| container_volume |
120 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792338992859971584 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:41:01.79Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Predictive+value+of+early+molecular+response+in+patients+with+chronic+myeloid+leukemia+treated+with+first-line+dasatinib&rft.date=2012-07-12&genre=article&issn=1528-0020&volume=120&issue=2&spage=291&epage=294&pages=291-294&jtitle=Blood&atitle=Predictive+value+of+early+molecular+response+in+patients+with+chronic+myeloid+leukemia+treated+with+first-line+dasatinib&aulast=O%27Brien&aufirst=Stephen&rft_id=info%3Adoi%2F10.1182%2Fblood-2012-01-407486&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792338992859971584 |
| author | Marin, David, Hedgley, Corinne, Clark, Richard E., Apperley, Jane, Foroni, Letizia, Milojkovic, Dragana, Pocock, Christopher, Goldman, John M., O'Brien, Stephen |
| author_facet | Marin, David, Hedgley, Corinne, Clark, Richard E., Apperley, Jane, Foroni, Letizia, Milojkovic, Dragana, Pocock, Christopher, Goldman, John M., O'Brien, Stephen, Marin, David, Hedgley, Corinne, Clark, Richard E., Apperley, Jane, Foroni, Letizia, Milojkovic, Dragana, Pocock, Christopher, Goldman, John M., O'Brien, Stephen |
| author_sort | marin, david |
| container_issue | 2 |
| container_start_page | 291 |
| container_title | Blood |
| container_volume | 120 |
| description | <jats:title>Abstract</jats:title> <jats:p>Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693.</jats:p> |
| doi_str_mv | 10.1182/blood-2012-01-407486 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDEyLTAxLTQwNzQ4Ng |
| imprint | American Society of Hematology, 2012 |
| imprint_str_mv | American Society of Hematology, 2012 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T15:41:01.79Z |
| match_str | marin2012predictivevalueofearlymolecularresponseinpatientswithchronicmyeloidleukemiatreatedwithfirstlinedasatinib |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 291-294 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Marin, David Hedgley, Corinne Clark, Richard E. Apperley, Jane Foroni, Letizia Milojkovic, Dragana Pocock, Christopher Goldman, John M. O'Brien, Stephen 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2012-01-407486 <jats:title>Abstract</jats:title> <jats:p>Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693.</jats:p> Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib Blood |
| spellingShingle | Marin, David, Hedgley, Corinne, Clark, Richard E., Apperley, Jane, Foroni, Letizia, Milojkovic, Dragana, Pocock, Christopher, Goldman, John M., O'Brien, Stephen, Blood, Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_full | Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_fullStr | Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_full_unstemmed | Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_short | Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_sort | predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| title_unstemmed | Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2012-01-407486 |